Anti-CD79 antibody induces B cell anergy that protects against autoimmunity.

Abstract

B cells play a major role in the pathogenesis of many autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and type I diabetes mellitus, as indicated by the efficacy of B cell-targeted therapies in these diseases. Therapeutic effects of the most commonly used B cell-targeted therapy, anti-CD20 mAb, are contingent upon long-term depletion of peripheral B cells. In this article, we describe an alternative approach involving the targeting of CD79, the transducer subunit of the B cell AgR. Unlike anti-CD20 mAbs, the protective effects of CD79-targeted mAbs do not require cell depletion; rather, they act by inducing an anergic-like state. Thus, we describe a novel B cell-targeted approach predicated on the induction of B cell anergy.

DOI: 10.4049/jimmunol.1302672

7 Figures and Tables

Statistics

0200400600201520162017
Citations per Year

127 Citations

Semantic Scholar estimates that this publication has 127 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Hardy2014AntiCD79AI, title={Anti-CD79 antibody induces B cell anergy that protects against autoimmunity.}, author={Ian R Hardy and Nadia Anceriz and François Rousseau and Matt B Seefeldt and Eric Hatterer and Magali Irla and Vanessa Buatois and Laurence E Chatel and Andrew Getahun and Ashley E. Fletcher and Laura Cons and Guillemette Pontini and Nicole A Hertzberg and Giovanni Magistrelli and Pauline Malinge and Mia J. Smith and W. Reith and Marie H. Kosco-Vilbois and Walter G Ferlin and John C Cambier}, journal={Journal of immunology}, year={2014}, volume={192 4}, pages={1641-50} }